Biogen Shares Plummet 8.17% on Sharp Drop in Alzheimer's Drug Hope
Biogen's stock price dropped 8.17% to $191.95, driven by concerns about its Alzheimer's treatment prospects. New data on diranersen, an anti-tau agent, showed a 26% slowing of cognitive decline. Meanwhile, LEQEMBI's at-home launch has Biogen investors reevaluating the company's growth prospects.
Biogen Inc.'s stock price plummeted to $191.95, marking an 8.17% drop following a sharp decline in confidence in its Alzheimer's treatment prospects. Recent news has sparked concerns about the company's growth prospects.
Despite this, new data on the anti-tau agent diranersen has provided a glimmer of hope. A phase 2 CELIA trial showed a 26% slowing of cognitive decline across multiple endpoints. This news was a positive development for the drug, which has been touted as a potential breakthrough in Alzheimer's treatment.
The launch of LEQEMBI in the home setting and new Alzheimer's data have Biogen investors questioning whether the stock has been undervalued. Analysts and investors alike are closely watching the company's future prospects as it continues to navigate the complex healthcare landscape.
Related Stocks
Powered by SentiSense - Intelligent Market Analysis